Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sep 29, 2009

Premium

Rob Parry has been appointed president and chief operating officer at BioMicro Systems, the firm said last week.

Parry has served as COO and vice president of manufacturing at Salt Lake City-based BioMicro since 2007. Prior to BioMicro, Parry held manufacturing positions at Hewlett Packard, Agilent Technologies, Fluidigm, and Nanosys.

Parry holds a BS in mechanical engineering from California Polytechnic State University in San Luis Obispo and an MS from the Massachusetts Institute of Technology in operations management and technology innovation.


Patrik Dahlén has been named chairman of the board at Olink Bioscience. Dahlén was CEO of global cancer diagnostics company Dako from 2005 to 2009.

Prior to his tenure at Dako, Dahlén was CEO of the Danish biotech company Biolmag. Before that, he was president of life sciences and senior vice president at PerkinElmer.

Ulf Landegren, Olink's co-founder and former chairman of the board, will continue to serve as a director, Olink Bio said.


Sequenom President and CEO Harry Stylli and Senior Vice President of R&D Elizabeth Dragon have been fired by the firm's board of directors, following an investigation into the mishandling of test data, Sequenom said this week.

In addition to those two executives, the firm said that Chief Financial Officer Paul Hawran and Steve Owings, vice president of commercial development for prenatal diagnostics, have resigned from the company, and three other employees have been fired. Stylli was also obligated to resign his position on Sequenom's board.

Sequenom's board appointed Chairman Harry Hixson, a former president and chief operating officer of Amgen, and Director Ronald Lindsay to serve on an interim basis as CEO and SVP of R&D, respectively. The board also has designated controller Justin File to serve as principal financial and accounting officer.

The clearout comes following the completion of an investigation into the mishandling of R&D test data and results on the firm's SEQureDx Down syndrome test. Sequenom disclosed the problems last April and opened an investigation at that time.

"While each of these officers and employees has denied wrongdoing, the special committee's investigation has raised serious concerns, resulting in a loss of confidence by the independent members of the company's board of directors in the personnel involved," the firm explained in a statement.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.